<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04891874</url>
  </required_header>
  <id_info>
    <org_study_id>Eastern HSH</org_study_id>
    <nct_id>NCT04891874</nct_id>
  </id_info>
  <brief_title>Adjuvant Radiotherapy for Resected Hepatocellular Carcinoma With MVI</brief_title>
  <official_title>Adjuvant Stereotactic Body Radiation for Hepatocellular Carcinoma With Microvascular Invasion and Narrow Resection Margin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eastern Hepatobiliary Surgery Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eastern Hepatobiliary Surgery Hospital</source>
  <brief_summary>
    <textblock>
      Positive micro vascular invasion in early stage hepatocellular carcinoma(HCC) leads to early&#xD;
      recurrence after surgery. Adjuvant external radiotherapy will be applied in those patients to&#xD;
      see if disease free survival and overall survival could be approved.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hepatocellular carcinoma(HCC) ranks the 6th most common cancer and is the 2nd leading cause&#xD;
      of cancer-related death globally. Surgical resection remains the most efficient therapy in&#xD;
      early stage. Though an anatomical resection of tumor lead to an up to 70% 5-year overall&#xD;
      survival, the existence of micro vascular invasion(MVI) caused early recurrence. Stereotactic&#xD;
      body radiation therapy (SBRT) has been proved to be efficient in treating vascular tumor&#xD;
      thrombosis. The investigators tried to implement this technique in adjuvant setting for HCC&#xD;
      after surgery with MVI. Participants with early stage HCC whose tumor locates closely to the&#xD;
      main intrahepatic vascular will be regarded as potentially-not-enough-surgical-margin&#xD;
      candidates. Surgical resection will be carried out as scheduled and an additional silver clip&#xD;
      will be put into the margin. Postoperative pathological examination will detect micro&#xD;
      vascular invasion or daughter nodule. MVI-positive candidates will be eligible for&#xD;
      enrollment. Eligible participants will be randomized to two groups, SBRT group and&#xD;
      surgery-alone(SA) group with 1-to-1 ratio. Participants in SBRT group will receive a 35Gy&#xD;
      limited resection margin parenchyma SBRT after surgery, while participants in SA group just&#xD;
      get surgery. Radiation related adverse events (AE) or reaction will be recorded and&#xD;
      intervened necessarily. All participants will be followed up by investigators every three&#xD;
      months. DFS, OS, and AEs are end points in this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2015</start_date>
  <completion_date type="Actual">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Adjuvant SBRT after surgery group vs. surgery alone group.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participants Without Recurrence (Disease-free).</measure>
    <time_frame>DFS rate at 5-years after randomization.</time_frame>
    <description>Participants will be monitored for recurrence(disease) since enrollment. DFS was defined as time interval from randomization to the first recurrence. The unit of measure was month.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) Rate.</measure>
    <time_frame>OS rate at 5-years from randomization.</time_frame>
    <description>OS was defined as time interval from randomization to death.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Participants Occured Adverse Events(AE)</measure>
    <time_frame>AE will be evaluated up to 3 months after radiotherapy in SBRT group</time_frame>
    <description>AE was defined as side effect related to the radiotherapy</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>SBRT group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in SBRT group will receive SBRT as adjuvant radiotherapy for hepatocellular carcinoma with microvascular invasion and narrow resection margin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Surgery alone group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants in surgery alone group will not receive any adjuvant therapy after surgery for hepatocellular carcinoma.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic radiotherapy</intervention_name>
    <description>Radiation using stereotactic radiotherapy device.</description>
    <arm_group_label>SBRT group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. solitary nodule;&#xD;
&#xD;
          2. tumor adjacent to the main trunk of hepatic vein, cava vena, or to the major branch of&#xD;
             portal vein (including the lobar branch at least);&#xD;
&#xD;
          3. macro-vascular negative;&#xD;
&#xD;
          4. no previous treatment before surgery;&#xD;
&#xD;
          5. no previous hepatic surgery;&#xD;
&#xD;
          6. Child-Pugh score A for hepatic function.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. spontaneous rupture;&#xD;
&#xD;
          2. pathologically proved positive resection margin;&#xD;
&#xD;
          3. severe cirrhosis with hypersplenism or esophageal and gastric varices;&#xD;
&#xD;
          4. 4-weeks postoperative examination revealed Î±-fetal protein(AFP) still positive or new&#xD;
             lesion in remnant liver;&#xD;
&#xD;
          5. postoperative complications required a secondary operation or more than 3&#xD;
             weeks'recovery from surgery.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jiamei Yang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Secondary Military Medical Unversity, Shanghai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Second Military Medical University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200438</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 12, 2021</study_first_submitted>
  <study_first_submitted_qc>May 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2021</study_first_posted>
  <results_first_submitted>June 22, 2021</results_first_submitted>
  <results_first_submitted_qc>August 14, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 10, 2021</results_first_posted>
  <last_update_submitted>August 14, 2021</last_update_submitted>
  <last_update_submitted_qc>August 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Eastern Hepatobiliary Surgery Hospital</investigator_affiliation>
    <investigator_full_name>Changying Shi</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Stereotactic body radiotherapy</keyword>
  <keyword>Micro vascular invasion</keyword>
  <keyword>Narrow resection margin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 1, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/74/NCT04891874/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 1, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/74/NCT04891874/SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 1, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/74/NCT04891874/ICF_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>SBRT Group</title>
          <description>Participants in SBRT group will receive SBRT as adjuvant radiotherapy for hepatocellular carcinoma with microvascular invasion and narrow resection margin.&#xD;
Stereotactic radiotherapy: Radiation using stereotactic radiotherapy device.</description>
        </group>
        <group group_id="P2">
          <title>Surgery Alone Group</title>
          <description>Participants in surgery alone group will not receive any adjuvant therapy after surgery for hepatocellular carcinoma.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="38">Participants in this period were recruited from August 1, 2015 to December 31, 2016.</participants>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>SBRT Group</title>
          <description>Participants in SBRT group will receive SBRT as adjuvant radiotherapy for hepatocellular carcinoma with microvascular invasion and narrow resection margin.&#xD;
Stereotactic radiotherapy: Radiation using stereotactic radiotherapy device.</description>
        </group>
        <group group_id="B2">
          <title>Surgery Alone Group</title>
          <description>Participants in surgery alone group will not receive any adjuvant therapy after surgery for hepatocellular carcinoma.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="38"/>
            <count group_id="B2" value="38"/>
            <count group_id="B3" value="76"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="69"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="76"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hepatitis Virus</title>
          <description>The participants with hepatitis virus were recoreded in the baseline characteristics. Difference between the two groups in hepatitis will be examed.</description>
          <units>Number of Participants With Hepatitis Vi</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Participants Without Recurrence (Disease-free).</title>
        <description>Participants will be monitored for recurrence(disease) since enrollment. DFS was defined as time interval from randomization to the first recurrence. The unit of measure was month.</description>
        <time_frame>DFS rate at 5-years after randomization.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SBRT Group</title>
            <description>Participants in SBRT group will receive SBRT as adjuvant radiotherapy for hepatocellular carcinoma with microvascular invasion and narrow resection margin.&#xD;
Stereotactic radiotherapy: Radiation using stereotactic radiotherapy device.</description>
          </group>
          <group group_id="O2">
            <title>Surgery Alone Group</title>
            <description>Participants in surgery alone group will not receive any adjuvant therapy after surgery for hepatocellular carcinoma.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants Without Recurrence (Disease-free).</title>
          <description>Participants will be monitored for recurrence(disease) since enrollment. DFS was defined as time interval from randomization to the first recurrence. The unit of measure was month.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS) Rate.</title>
        <description>OS was defined as time interval from randomization to death.</description>
        <time_frame>OS rate at 5-years from randomization.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SBRT Group</title>
            <description>Participants in SBRT group will receive SBRT as adjuvant radiotherapy for hepatocellular carcinoma with microvascular invasion and narrow resection margin.&#xD;
Stereotactic radiotherapy: Radiation using stereotactic radiotherapy device.</description>
          </group>
          <group group_id="O2">
            <title>Surgery Alone Group</title>
            <description>Participants in surgery alone group will not receive any adjuvant therapy after surgery for hepatocellular carcinoma.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS) Rate.</title>
          <description>OS was defined as time interval from randomization to death.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants Occured Adverse Events(AE)</title>
        <description>AE was defined as side effect related to the radiotherapy</description>
        <time_frame>AE will be evaluated up to 3 months after radiotherapy in SBRT group</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SBRT Group</title>
            <description>Participants in SBRT group will receive SBRT as adjuvant radiotherapy for hepatocellular carcinoma with microvascular invasion and narrow resection margin.&#xD;
Stereotactic radiotherapy: Radiation using stereotactic radiotherapy device.</description>
          </group>
          <group group_id="O2">
            <title>Surgery Alone Group</title>
            <description>Participants in surgery alone group will not receive any adjuvant therapy after surgery for hepatocellular carcinoma.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Occured Adverse Events(AE)</title>
          <description>AE was defined as side effect related to the radiotherapy</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months from radiotherapy.</time_frame>
      <desc>The adverse events were reported according to the CTCAE 5.0 version.</desc>
      <group_list>
        <group group_id="E1">
          <title>SBRT Group</title>
          <description>Participants in SBRT group will receive SBRT as adjuvant radiotherapy for hepatocellular carcinoma with microvascular invasion and narrow resection margin. The AE like fatigue, vomitting, skin reaction and other items according to CTCAE5.0 will be recorded.</description>
        </group>
        <group group_id="E2">
          <title>Surgery Alone Group</title>
          <description>Participants in surgery alone group will not receive any adjuvant therapy after surgery for hepatocellular carcinoma.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE(5.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Myelosuppression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Dyspepsea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Liver injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. SHI Changying</name_or_title>
      <organization>Shanghai Eastern Hepatobiliary Surgery Hospital</organization>
      <phone>+86-021-81887735</phone>
      <email>nona-peach@hotmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

